The short version of reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-16 and is reviewed periodically as new material appears.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
At the beginning of the season, Zverev was still ranked too low to receive direct entry into the main draws of ATP Tour events, which forced him to continue playing Challenger events through July. He also needed to enter qualifying for ATP events throughout the year. Zverev did not qualify for either of the first two major singles events of the season. He was able to qualify for his first Masters event at the Miami Open and reached the second round. During the clay-court season, Zverev partnered with his brother Mischa to reach his first career ATP final in doubles at the Bavarian International Tennis Championships. The Zverev brothers finished runner-up to top-seeded Alexander Peya and Bruno Soares. Later that month, he won his second career Challenger title at the Heilbronn Neckarcup to crack the top 100 of the ATP rankings. With a higher ranking, Zverev was directly accepted into Wimbledon. A week before the tournament, he took part in the Boodles Challenge exhibition and surprisingly upset world No. 1 Novak Djokovic in straight sets. Zverev backed up this performance in his Grand Slam tournament main draw debut, defeating Teymuraz Gabashvili in a tight match that lasted until 9–7 in the fifth and final set. He lost in the next round to Denis Kudla. Zverev opted to play on clay after Wimbledon and reached another ATP semifinal at the Swedish Open to put him back in the top 100 after one week out. In August, Zverev returned to the United States and competed in two US Open Series events. He notably upset No.
== Enzymes == Glycogen phosphorylase with Pyridoxal phosphate as prosthetic group Alpha-1,4 → alpha-1,4 glucan transferase Alpha-1,6-glucosidase Phosphoglucomutase Glucose-6-phosphatase (absent in muscles)
=== Sex-work and HIV === Despite the depth of knowledge of HIV/AIDS, rapid transmission has occurred globally in sex workers. The relationship between these two variables greatly increases the risk of transmission among these populations, and also to anyone associated with them, such as their sexual partners, their children, and eventually the population at large. Many street-level harm-reduction strategies have succeeded in reducing HIV transmission in injecting drug users and sex-workers. HIV education, HIV testing, condom use, and safer-sex negotiation greatly decreases the risk to the disease. Peer education as a harm reduction strategy has especially reduced the risk of HIV infection, such as in Chad, where this method was the most cost-effective per infection prevented. Decriminalisation as a harm-reduction strategy gives the ability to treat substance use disorder solely as a public health issue rather than a criminal activity. This enables other harm-reduction strategies to be employed, which results in a lower incidence of HIV infection. One of the first harm reduction models was called the "Mersey Harm Reduction Model" in 1980s Liverpool, and the success of utilizing outreach workers, distribution of education, and providing clean equipment to drug users was shown in the fact that an HIV epidemic did not happen in Mersey. The AIDS epidemic, which began in the 80s and peaked in 1995, further complicated the politicization of drug users and drug use in the US.
A proteolipid is a protein covalently linked to lipid molecules, which can be fatty acids, isoprenoids or sterols. The process of such a linkage is known as protein lipidation, and falls into the wider category of acylation and post-translational modification. Proteolipids are abundant in brain tissue, and are also present in many other animal and plant tissues. They include ghrelin, a peptide hormone associated with feeding. Many proteolipids have bound fatty acid chains, which often provide an interface for interacting with biological membranes and act as lipidons that direct proteins to specific zones. Proteolipids were discovered serendipitously in 1951 by Jordi Folch Pi and Marjorie Lees while extracting sulfatides from brain lipids. They are not to be confused with lipoproteins, a kind of spherical assembly made up of many molecules of lipids and some apolipoproteins.
It was later revealed that Fripp had attempted to replace himself with McDonald and Steve Hackett of Genesis, but this was rejected by the managers. Following the band's disbandment, the live album USA was released in May 1975, formed of recordings from their 1974 North American tour. It received some positive reviews, including being deemed "a must" for fans of the band and "insanity you're better off having". Issues with the tapes rendered some of Cross's playing inaudible, so Eddie Jobson of Roxy Music was hired to perform violin and keyboard overdubs; further edits were also made to allow the music to fit on a single LP. More live recordings from the 1972–1974 era would be issued as The Night Watch in 1997, and as part of the box sets The Great Deceiver (1992), Larks' Tongues in Aspic (1972–1973) (2012), The Road to Red (1974), and Starless (1973–1974) (both 2014). After short stints with Roxy Music and Uriah Heep, Wetton went on to co-form U.K. with Bruford in 1977, and Asia in 1981; Bruford, in addition to U.K., formed the jazz fusion band Bruford. From 1975 to 1980, King Crimson were completely inactive.
Sources: en.wikipedia.org
1993/3253) Customs Duties (ECSC) (Quota and other Reliefs) Order 1993 (S.I. 1993/3254) Medicines (Products Other Than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1993 (S.I. 1993/3256) Tribunals and Inquiries (Friendly Societies) Order 1993 (S.I. 1993/3258) Cardiff—Glan Conwy Trunk Road (A470) (Pentrebach—Cefn Coed Diversion) Order 1993 (S.I. 1993/3259) London Borough of Hackney (Lea Bridge-Cycle/Footbridge) Scheme 1993 Confirmation Instrument 1993 (S.I. 1993/3260) M42 Motorway (Junction 6 Southbound Off-Slip Road to Eastway) Scheme 1993 (S.I. 1993/3261) Export of Goods (Control) (Amendment No. 6) Order 1993 (S.I. 1993/3264) County Court (Amendment No. 4) Rules 1993 (S.I. 1993/3273) Land Registration Rules 1993 (S.I. 1993/3275) Land Registration (Official Searches) Rules 1993 (S.I. 1993/3276)
Some hydrothermal vents form roughly cylindrical chimney structures. These form from minerals that are dissolved in the vent fluid. When the superheated water contacts the near-freezing sea water, the minerals precipitate out to form particles which add to the height of the stacks. Some of these chimney structures can reach heights of 60 m (200 ft). An example of such a towering vent was "Godzilla", a structure on the Pacific Ocean deep seafloor near Oregon that rose to 40 m (130 ft) before it fell over in 1996.
African American Cultural Complex Contemporary Art Museum of Raleigh Gregg Museum of Art & Design at North Carolina State University Haywood Hall House & Gardens Marbles Kids Museum North Carolina Museum of Art North Carolina Museum of History North Carolina Museum of Natural Sciences North Carolina Sports Hall of Fame City of Raleigh Museum J. C. Raulston Arboretum Joel Lane House Mordecai Plantation Pope House Museum
==== MeSH D06.472.040 – adrenal cortex hormones ==== MeSH D06.472.040.502 – 17-ketosteroids MeSH D06.472.040.502.112 – androstenedione MeSH D06.472.040.502.195 – androsterone MeSH D06.472.040.502.497 – estrone MeSH D06.472.040.502.583 – etiocholanolone MeSH D06.472.040.502.620 – dehydroepiandrosterone MeSH D06.472.040.502.620.300 – dehydroepiandrosterone sulfate MeSH D06.472.040.585 – hydroxycorticosteroids MeSH D06.472.040.585.353 – 11-hydroxycorticosteroids MeSH D06.472.040.585.353.118 – aldosterone MeSH D06.472.040.585.353.237 – corticosterone MeSH D06.472.040.585.353.476 – hydrocortisone MeSH D06.472.040.585.353.500 – 18-hydroxycorticosterone MeSH D06.472.040.585.353.825 – tetrahydrocortisol MeSH D06.472.040.585.478 – 17-hydroxycorticosteroids MeSH D06.472.040.585.478.195 – cortisone MeSH D06.472.040.585.478.225 – cortodoxone MeSH D06.472.040.585.478.392 – hydrocortisone MeSH D06.472.040.585.478.782 – tetrahydrocortisol MeSH D06.472.040.585.478.865 – tetrahydrocortisone MeSH D06.472.040.585.611 – desoxycorticosterone MeSH D06.472.040.585.611.400 – 18-hydroxydesoxycorticosterone MeSH D06.472.040.585.745 – pregnenolone MeSH D06.472.040.585.745.500 – 17-alpha-hydroxypregnenolone
== Activism, research centers == The Center for Orphan Drug Research at the University of Minnesota College of Pharmacy helps small companies with insufficient in-house expertise and resources in drug synthesis, formulation, pharmacometrics, and bio-analysis. The Keck Graduate Institute Center for Rare Disease Therapies (CRDT) in Claremont, California, supports projects to revive potential orphan drugs whose development has stalled by identifying barriers to commercialization, such as problems with formulation and bio-processing. Numerous advocacy groups such as the National Organization for Rare Disorders, Global Genes Project, Children's Rare Disease Network, Abetalipoproteinemia Collaboration Foundation, Zellweger Baby Support Network, and the Friedreich's Ataxia Research Alliance have been founded in order to advocate on behalf of patients with rare diseases with a particular emphasis on diseases that affect children.
Sources: en.wikipedia.org
=== Computing, environmental, and interdisciplinary research === The National Science Foundation funded the iPlant Collaborative in 2008 with a $50 million grant. In 2013, iPlant Collaborative received a $50 million renewal grant. Rebranded in late 2015 as "CyVerse", the collaborative cloud-based data management platform is moving beyond life sciences to provide cloud-computing access across all scientific disciplines. In June 2011, the university announced it would assume full ownership of the Biosphere 2 scientific research facility in Oracle, Arizona. Biosphere 2 was constructed by private developers (funded mainly by Texas businessman and philanthropist Ed Bass) with its first closed system experiment commencing in 1991. The university had been the official management partner of the facility for research purposes since 2007.
== History == In the 1950s, major breakthroughs in psychopharmacology occurred around the world. Then throughout the 1960s and 1970s major advances were made in synthesizing and identifying psychoactive drugs which were useful in the treatment of various mental disorders. Here, scientists had realised that these drugs interact with receptors located on neurons that led to changes in neural functioning. The connection was made shortly after the discovery of catecholamines having effects on emotion, relating to depression, and was of wide interest. Discovery was made on the decreased levels of certain neurotransmitters, catecholamines such as norepinephrine, dopamine and serotonin, and their role in the pathogenesis of depression. These past discoveries in psychopharmacology led to the development of antidepressants and a range of drugs with different functions on those neurotransmitters. But a new generation of antidepressants were resulted from the discovery of selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine). Although SSRIs are a group of effective antidepressant drugs with considerably few severe side effects, they are not universally effective and can also have a few unpleasant side effects, such as weight gain, sleep disturbances and anxiety. Pharmacologically and chemically unrelated to SSRIs, the past four decades, norepinephrine has been asserted to play an important, possibly primary, role in the treatment of mental disorders.
Absorption of cadmium through the lungs is more effective than through the gut. As much as 50% of the cadmium inhaled in cigarette smoke may be absorbed. On average, cadmium concentrations in the blood of smokers is 4 to 5 times greater than non-smokers and in the kidney, 2–3 times greater than in non-smokers. Despite the high cadmium content in cigarette smoke, there seems to be little exposure to cadmium from passive smoking. In a non-smoking population, food accounts for around 90% of cadmium uptake. High quantities of cadmium can be found in crustaceans, mollusks, offal, frog legs, cocoa powder, bitter and semi-bitter chocolate, seaweed, fungi and algae products. However, grains, vegetables, and starchy roots and tubers are consumed in much greater quantity in the U.S., and are the source of the greatest dietary exposure there. Most plants bio-accumulate metal toxins such as cadmium and when composted to form organic fertilizers, yield a product that often can contain high amounts (e.g., over 0.5 mg) of metal toxins for every kilogram of fertilizer. Fertilizers made from animal dung (e.g., cow dung) or urban waste can contain similar amounts of cadmium. The cadmium added to the soil from fertilizers (rock phosphates or organic fertilizers) become bio-available and toxic only if the soil pH is low (i.e., acidic soils). In the European Union, an analysis of almost 22,000 topsoil samples with LUCAS survey concluded that 5.5% of samples have concentrations higher than 1 mg kg−1.
== Pro-Soviet accounts == Soviet historiography on the Cold War era was overwhelmingly dictated by the Soviet state, and blamed the West for the Cold War. In Britain, the historian E. H. Carr wrote a 14-volume history of the Soviet Union, which was focused on the 1920s and published 1950–1978. His friend R. W. Davies said Carr belonged to the anti-Cold War school of history, which regarded the Soviet Union as the major progressive force in the world, the United States as the world's principal obstacle to the advancement of humanity and the Cold War as a case of American aggression against the Soviet Union. Carr criticized those Anglophone historians, who he felt had unfairly judged the Soviet Union by the cultural norms of Britain and the United States.
==== Monoamine oxidase B (MAO-B) inhibitors ==== Rasagiline (Agilect; AGN-1135; Azilect; Elbrus; Lu-00-773; TV-1030; TVP-101; TVP-1012) – monoamine oxidase B (MAO-B) inhibitor [338] Safinamide (EMD-1195686; Equfina; FCE-26743; ME-2125; NW-1015; Onstryv; PNU-151774; Xadago; ZP-034) – reversible monoamine oxidase B (MAO-B) inhibitor and other actions [339] Selegiline (Eldepryl, Jumex) – monoamine oxidase B (MAO-B) inhibitor and other actions Selegiline orally disintegrating tablet (Efupi; FPF-1100-NW; selegiline ODT) – monoamine oxidase B (MAO-B) inhibitor and other actions [340]
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.